Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of ¹⁷⁷Lu-Nimotuzumab

References

• Calzada V, Zhang X, Fernández M, Díaz-Miqueli A, Iznaga-Escobar NL, Deutscher S, Balter HP, Quinn T, Cabral P. 2012. A potential theranostic agent for EGF-R expression tumors: (177) Lu-DOTA-nimotuzumab . Curr Radiopharm. 5(4):318–324.
   PubMedGoogle Scholar
• Ciardiello F, Tortora G. 2003. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 39(10):1348–1354.
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. 2002. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer. 101(6):567–575.
   PubMed Web of Science ®Google Scholar
• Dash A, Pillai MR, Knapp FF. 2015. Production of (177) Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 49(2):85–107.
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. 2011. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 11(4):373–382.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Langer CJ. 2002. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 29(1 Suppl 4):27–36.
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Murley JS, Baker KL, Grdina DJ. 2007. Relationship between phosphorylated histone H2AX formation and cell survival in human microvascular endothelial cells (HMEC) as a function of ionizing radiation exposure in the presence or absence of thiol-containing drugs. Radiat Res. 168(1):106–114.
   PubMed Web of Science ®Google Scholar
• Lin S, Yan Y, Liu Y, Gao CZ, Shan D, Li Y, Han B. 2015. Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase. Cell Biol Int. 39(2):146–151.
   PubMed Web of Science ®Google Scholar
• Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. 2018. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 45(1–2):18–28.
   PubMed Web of Science ®Google Scholar
• Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J, et al. 2006. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjug Chem. 17(2):485–492.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 366(1):2–16.
   PubMed Web of Science ®Google Scholar
• Oda K, Matsuoka Y, Funahashi A, Kitano H. 2005. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 1(1):2005.0010.
   PubMedGoogle Scholar
• Pandey U, Kameswaran M, Gamre N, Dash A. 2019. Preparation of 177 Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: comparison of DOTA and CHX-A″-DTPA as bifunctional chelators . J Labelled Comp Radiopharm. 62(4):158–165.
   PubMed Web of Science ®Google Scholar
• Perry ME. 2004. Mdm2 in the response to radiation. Mol Cancer Res. 2(1):9–19.
   PubMed Web of Science ®Google Scholar
• Phelps D, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva RT, Middleton S, Wang D, Mo X, Houghton PJ. 2015. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Pediatr Blood Cancer. 62(8):1345–1352.
   PubMed Web of Science ®Google Scholar
• Qu YY, Hu SL, Xu XY, Wang RZ, Yu HY, Xu JY, Chen L, Dong GL. 2013. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair. PLoS One. 8(8):e70727.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS. 2009. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 1(1):41–48.
   PubMed Web of Science ®Google Scholar
• Rivera F, Eugenia Vega-Villegas M, Lopez-Brea MF, Marquez R. 2008. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 47(1):9–19.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, et al. 2012. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 30(3):1138–1143.
   PubMed Web of Science ®Google Scholar
• Tang Y, Hu Y, Liu W, Chen L, Zhao Y, Ma H, Yang J, Yang Y, Liao J, Cai J, et al. 2019. A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo . Nucl Med Biol. 70:23–31.
   PubMed Web of Science ®Google Scholar
• Teng K, Zhang Y, Hu X, Ding Y, Gong R, Liu L. 2015. Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair. Onco Targets Ther. 8:809–818.
   PubMed Web of Science ®Google Scholar
• Vera DR, Eigner S, Beran M, Henke KE, Laznickova A, Laznicek M, Melichar F, Chinol M. 2011. Preclinical evaluation of (177)Lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 26(3):287–297.
   PubMed Web of Science ®Google Scholar
• Vera DR, Eigner S, Henke KE, Lebeda O, Melichar F, Beran M. 2012. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol. 39(1):3–13.
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Moasser MM. 2008. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 65(10):1566–1584.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang S, Yin L, Yang Y, Guan Y, Wang W, Xu H, Tao N. 2015. Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal Chem. 87(19):9960–9965.
   PubMed Web of Science ®Google Scholar